News · 26 weeks160-55%
2026-03-012026-08-23
Mix5790d
- SEC Filings46(81%)
- Other8(14%)
- Analyst2(4%)
- Offering1(2%)
Latest news
25 items- PRCPE Media & Data Company: Lowest Level of International Venture Capital Funding - Canadian VC H1 2026All dollar ($) figures in Canadian dollars unless otherwise noted.TORONTO, Aug. 24, 2026 /CNW/ -- Canadian venture capital (VC) investment totalled $2.481 billion across 248 financings in the first half of 2026, representing a 12% decline from $3.215 billion and a 19% decrease from 306 financings in H1 2025, according to the H1 2026 Canadian Venture Capital Report – Summary Report released by CPE Analytics.International investor participation continued to soften through the first half of 2026, while U.S. investors increased their activity in Q2, with their share of Canadian VC investment rising to 56% from 40% in Q1 2026—nearly matching the 2025 high of 58%.On the VC fundraising front, 29 Ca
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by GSK plcSCHEDULE 13G/A - GSK plc (0001131399) (Subject)
- SECSEC Form 13F-HR filed by GSK plc13F-HR - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- PRNew survey reveals Canadians underestimate chronic hepatitis B and its link to liver cancerNearly 9 in 10 Canadians have little to no awareness of chronic hepatitis B (CHB)Only 31% rank CHB as a high cancer risk, revealing a significant gap between perception and realityJust 14% report to have been tested for CHB, yet CHB causes 56%2 of liver cancer cases and affects over 262,000 in Canada3MISSISSAUGA, ON, July 28, 2026 /CNW/ -- GSK plc (LSE: GSK) (NYSE: GSK) today released new data insights from a global survey marking World Hepatitis Day. The global survey, funded and commissioned by GSK, revealed major gaps in public awareness of chronic hepatitis B (CHB) in Canada, with many adults underestimating the role of CHB in liver cancer.1
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- ANALYSTCitigroup initiated coverage on GSK plcCitigroup initiated coverage of GSK plc with a rating of Neutral
- PRJideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancerApproval based on ARROS-1 phase I/II trial demonstrating meaningful and durable responses in patients with locally advanced or metastatic disease1Next-generation design aims to address key efficacy and tolerability challenges of treating ROS1-positive NSCLCGSK's first approval in lung cancer, part of a growing portfolio of targeted treatmentsLONDON, July 22, 2026 /PRNewswire/ -- GSK plc (LSE/NYSE:GSK) today announced the US Food and Drug Administration (FDA) has approved Jideytro (zidesamtinib), a ROS1 selective inhibitor, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor.1 The a
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
GSK FAQ
7 questionsWhat does GSK plc do?
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system...Where does GSK stock trade?
GSK plc (GSK) is listed on NYSE.What sector and industry is GSK in?
GSK plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did GSK plc go public?
GSK plc (GSK) completed its IPO in 2022.What are analysts saying about GSK?
GSK plc has had 8 recent analyst actions on file. The most recent action was from Citigroup: Neutral on 2026-07-24. Recent price targets cluster around $3525.00.What companies are similar to GSK?
Notable peers in the same industry include JNJ (Johnson & Johnson), NVS (Novartis AG), AZN (AstraZeneca PLC), SNY (Sanofi). Compare GSK side-by-side with any of them on Quantisnow.How can I track GSK on Quantisnow?
Quantisnow aggregates GSK plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GSK to receive live email and push alerts on every new disclosure.